Mitral valve articles

EuroPCR 2020 | EVOQUE: nuevo sistema de reemplazo mitral por catéter, promesas a corto plazo y esperanzas para el futuro

EuroPCR 2020 | CLASP: New Device for Mitral Repair with at One Year Follow Up

EuroPCR 2020 | CLASP: New Device for Mitral Repair with at One Year Follow Up

The CLASP looked into patients treated with the new device for transcatheter mitral repair called PASCAL and showed low complications rate, high survival rate, significant mitral regurgitation reduction and improved quality of life at one year.  In July 2019 we published on our web page the 30 year outcomes of the PASCAL device () which

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

Promising Outcomes of Transcatheter Mitral Valve Replacement in Complex Patients

Courtesy of Dr. Carlos Fava. The risk of repeat surgical mitral valve repair involves 6% to15% mortality at 30 days, even close to 20% in acute cases. However, mortality can rise to over 40% when it comes to a third or fourth surgical intervention.  One of the solutions to this serious problem is transcatheter mitral

Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points

After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations for cardiac failure at long term follow-up.  Improved quality of life had already been presented, exactly one year ago at the ACC 2019. In that occasion, it was established that the MitraClip reduces symptoms

ACC Virtual 2020 | A diferencia del TAVI, el volumen de cirugías mitrales no mejora la reparación por catéter

Virtual ACC 2020 | Unlike in TAVR, the Number of Mitral Valve Surgeries Does Not Improve the Outcomes of Transcatheter Mitral Valve Repairs

Soon, our website will feature an interesting study showing that sites with a higher number of conventional surgical aortic valve replacements had better outcomes in transcatheter aortic valve replacement procedures. The study featured in this article was scheduled for presentation at the American College of Cardiology 2020 Scientific Session along the World Congress of Cardiology.

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

Percutaneous Annuloplasty in Functional Mitral Regurgitation vs. Sham Procedure

In cases where it is difficult to demonstrate the improvement of a drug or a device in hard endpoints such as mortality, we should look for softer and easier to prove endpoints. The problem is that these soft endpoints are often subjective (such as sensation of shortness of breath or angina pectoris) and they could

Las ondas venosas pulmonares en el MitraClip tienen valor pronóstico

1000 MitraClips: Results from the World’s Most Experienced Site

In September 2008, interventional physicians at the Heart and Vascular Centre Hamburg conducted the first MitraClip implantation after its Conformité Européenne (CE)-marking approval. In July 2019, the same site reached an amazing milestone, 1000 MitraClips implanted, and in doing so it became the most experienced site in the world. Those 1000 patients treated had an average logistic

TCT 2019 | PARTNER 2A at 5 Years: In Intermediate-Risk Patients, TAVR Is Still Head-to-Head with Surgery

Courtesy of the SBHCI. The 2-year results of the PARTNER 2A trial showed that transcatheter aortic valve implantation has a result similar to that of surgery in patients with aortic stenosis and intermediate surgical risk. We lacked long-term data, both clinical and related to prosthesis function. Now, at TCT 2019, researchers presented the 5-year data for this

Highlights TCT 2019

TCT 2019 | Mitral Valve-in-Valve: 1-Year Results for Sapien 3 in Mitral Valve Replacement for Degenerated Bioprostheses

Courtesy of SBHCI. The aim of this work was to assess the contemporary outcomes of mitral valve-in-valve using Sapien 3 prostheses, see the differences between trasapical and transseptal access, and establish 1-year mortality predictors. Researchers analyzed retrospectively the data from the Society of Thoracic Surgeons [STS]/American College of Cardiology TVT Registry, which included 1576 patients who had

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

MitraClip in the Real World: Mid-Term Progress

Courtesy of Dr. Carlos Fava. The fact that the outcomes of edge-to-edge repair with MitraClip have improved, particularly in the immediate and short term, is widely known. Such improvement is basically a result of more operator experience and the arrival of 3-D echocardiography. However, there are no mid-term follow-up studies available, except for the EVEREST

ESC 2019 | MITRA-FR: los resultados a 2 años de uno de los grandes estudios del MitraClip

ESC 2019 | MITRA-FR: 2-Year Outcomes of One of the Largest Studies on MitraClip

Negative one-year outcomes of Mitra-FR led to several discussions and hypothesis, especially after the COAPT was published only a few weeks later. According to the COAPT study, the MitraClip was able to reduce hospitalization rate for cardiac failure and also all-cause mortality, compared against optimal medical treatment alone. When comparing the COAPT to the Mitra-FR,

Top